J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies

Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared…

Read More

KFF Standards and Practices

KFF Standards and Practices Published: January 13, 2025 Introduction This document’s intent is to serve as a roadmap that sets expectations clearly for how we work together and behave in a principled and ethical manner. It applies equally to all KFF staff across the board as well as for any freelancers doing work under our…More

Read More

La inteligencia artificial iba a reducir los costos de salud, pero resulta que necesita de costosos seres humanos

Una de las tareas del oncólogo es preparar a los pacientes con cáncer para tomar decisiones difíciles cuando se acerca el final. Sin embargo, no siempre se acuerdan de hacerlo. En el sistema de salud de la Universidad de Pennsylvania (Penn Medicine), un algoritmo de inteligencia artificial (IA) que predice las probabilidades de muerte de…

Read More

Prioritize Provider Data for Seamless M&A Success

Health systems preparing for an M&A, or even those not immediately considering one, must prioritize a robust workforce data strategy. This approach is essential for navigating today’s increasingly frequent healthcare consolidations. The post Prioritize Provider Data for Seamless M&A Success appeared first on MedCity News.

Read More